← Back to Search

Cancer Metabolism Inhibitor

RLY-1971 for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion (an average of one year)
Awards & highlights

Summary

This trial tests a new drug called RLY-1971 in patients with advanced or spreading cancers. It aims to find the safest dose, understand how the drug is processed by the body, and see if it can shrink tumors.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion (an average of one year)
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion (an average of one year) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum Tolerated Dose (MTD)
Recommended Phase 2 Dose (RP2D)
Secondary study objectives
Disease Control Rate (DCR)
Objective Response Rate (ORR)
Plasma concentration levels of RLY-1971
Other study objectives
Changes in phospho-ERK levels
Duration of Response (DOR)
Progression-free Survival (PFS)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: RLY-1971 - Dose Escalation/ExpansionExperimental Treatment1 Intervention
Dose Escalation: Oral dose of RLY-1971 until Maximum Tolerated Dose (MTD), and Recommended Phase 2 dose (RP2D) are identified Dose Expansion: Oral dose of RLY-1971 once Maximum Tolerated Dose (MTD), and Recommended Phase 2 Dose (RP2D) are identified.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RLY-1971
2020
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,444 Previous Clinical Trials
1,093,066 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,212 Previous Clinical Trials
892,360 Total Patients Enrolled
~10 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top